Adam M Leventhal1, Wonho Lee2, Andrew W Bergen3, Gary E Swan3, Rachel F Tyndale4, Caryn Lerman5, David V Conti2. 1. Department of Preventive Medicine, University of Southern California, Los Angeles, CA 90033, USA; Department of Psychology, University of Southern California, Los Angeles, CA 90033, USA. Electronic address: adam.leventhal@usc.edu. 2. Department of Preventive Medicine, University of Southern California, Los Angeles, CA 90033, USA. 3. Center for Health Sciences, SRI International, Menlo Park, CA 94025, USA. 4. Centre for Addiction and Mental Health and Departments of Psychiatry, Pharmacology and Toxicology, University of Toronto, Toronto, ON, ON M5S 1A1 Canada. 5. Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, USA.
Abstract
BACKGROUND: Genetic influences on smoking cessation treatment outcome may be affected by pretreatment patient characteristics. Nicotine dependence is arguably the most salient clinical factor in smoking cessation. METHODS: In this secondary analysis of clinical trial data (N=793), we examined nicotine dependence severity as a moderator of the effects of 1198 single nucleotide polymorphisms (SNPs) in 53 biologically-relevant gene regions on smoking cessation outcomes. P-values were adjusted to account for multiple correlated SNPs within a gene region; corrected system-wide significance was 5 × 10(-4). RESULTS: SNP × nicotine dependence interactions reached region-wide significance for several SNPs in the Dopamine Beta Hydroxylase (DBH) locus (0.0005<Adjusted-P<0.05), including rs1541333, which reached system-wide significance for predicting end of treatment (EOT) abstinence (Adjusted-P=0.0004). A haplotype including 6 DBH SNPs predicted abstinence at EOT (OR=1.7, P=0.001) and 6-month follow-up (OR=1.6, P=0.008) in those with high nicotine dependence (n=526) but not in those with low dependence (n=227). The DBH signal observed here may be distinct from a previously reported genome-wide significant signal for former smoking status and from the principal haplotype associated with plasma dopamine beta-hydroxylase activity. A haplotype within the Chromosome 15 Nicotinic Acetylcholine Receptor gene region predicted abstinence at EOT in those with high (OR=2.0, P=0.0004) but not low (P=0.6) dependence in post hoc analyses. CONCLUSIONS: Considering pre-treatment nicotine dependence level may optimize the prediction of genetic influences on cessation outcomes. If replicated, results like these may inform prognosticative genomic screening panels designed to identify smokers at high risk of relapse when coupled with severe nicotine dependence.
BACKGROUND: Genetic influences on smoking cessation treatment outcome may be affected by pretreatment patient characteristics. Nicotine dependence is arguably the most salient clinical factor in smoking cessation. METHODS: In this secondary analysis of clinical trial data (N=793), we examined nicotine dependence severity as a moderator of the effects of 1198 single nucleotide polymorphisms (SNPs) in 53 biologically-relevant gene regions on smoking cessation outcomes. P-values were adjusted to account for multiple correlated SNPs within a gene region; corrected system-wide significance was 5 × 10(-4). RESULTS: SNP × nicotine dependence interactions reached region-wide significance for several SNPs in the Dopamine Beta Hydroxylase (DBH) locus (0.0005<Adjusted-P<0.05), including rs1541333, which reached system-wide significance for predicting end of treatment (EOT) abstinence (Adjusted-P=0.0004). A haplotype including 6 DBH SNPs predicted abstinence at EOT (OR=1.7, P=0.001) and 6-month follow-up (OR=1.6, P=0.008) in those with high nicotine dependence (n=526) but not in those with low dependence (n=227). The DBH signal observed here may be distinct from a previously reported genome-wide significant signal for former smoking status and from the principal haplotype associated with plasma dopamine beta-hydroxylase activity. A haplotype within the Chromosome 15 Nicotinic Acetylcholine Receptor gene region predicted abstinence at EOT in those with high (OR=2.0, P=0.0004) but not low (P=0.6) dependence in post hoc analyses. CONCLUSIONS: Considering pre-treatment nicotine dependence level may optimize the prediction of genetic influences on cessation outcomes. If replicated, results like these may inform prognosticative genomic screening panels designed to identify smokers at high risk of relapse when coupled with severe nicotine dependence.
Authors: Anna M Lee; Christopher Jepson; Ewa Hoffmann; Leonard Epstein; Larry W Hawk; Caryn Lerman; Rachel F Tyndale Journal: Biol Psychiatry Date: 2007-01-16 Impact factor: 13.382
Authors: F Patterson; R A Schnoll; E P Wileyto; A Pinto; L H Epstein; P G Shields; L W Hawk; R F Tyndale; N Benowitz; C Lerman Journal: Clin Pharmacol Ther Date: 2008-04-02 Impact factor: 6.875
Authors: Viba Malaiyandi; Shari D Goodz; Edward M Sellers; Rachel F Tyndale Journal: Cancer Epidemiol Biomarkers Prev Date: 2006-10 Impact factor: 4.254
Authors: Timothy B Baker; Megan E Piper; Danielle E McCarthy; Daniel M Bolt; Stevens S Smith; Su-Young Kim; Suzanne Colby; David Conti; Gary A Giovino; Dorothy Hatsukami; Andrew Hyland; Suchitra Krishnan-Sarin; Raymond Niaura; Kenneth A Perkins; Benjamin A Toll Journal: Nicotine Tob Res Date: 2007-11 Impact factor: 4.244
Authors: Sean P David; Richard A Brown; George D Papandonatos; Christopher W Kahler; Elizabeth E Lloyd-Richardson; Marcus R Munafò; Peter G Shields; Caryn Lerman; David Strong; Jeanne McCaffery; Raymond Niaura Journal: Nicotine Tob Res Date: 2007-08 Impact factor: 4.244
Authors: George R Uhl; Qing-Rong Liu; Tomas Drgon; Catherine Johnson; Donna Walther; Jed E Rose; Sean P David; Ray Niaura; Caryn Lerman Journal: Arch Gen Psychiatry Date: 2008-06
Authors: Sean P David; David R Strong; Marcus R Munafò; Richard A Brown; Elizabeth E Lloyd-Richardson; Paul E Wileyto; Eden A Evins; Peter G Shields; Caryn Lerman; Raymond Niaura Journal: Nicotine Tob Res Date: 2007-12 Impact factor: 4.244
Authors: Matthew Randesi; Wim van den Brink; Orna Levran; Vadim Yuferov; Peter Blanken; Jan M van Ree; Jurg Ott; Mary Jeanne Kreek Journal: Pharmacogenomics Date: 2017-12-06 Impact factor: 2.533
Authors: Paul T Harrell; Hui-Yi Lin; Jong Y Park; Melissa D Blank; David J Drobes; David E Evans Journal: Psychopharmacology (Berl) Date: 2016-01 Impact factor: 4.530
Authors: Ewoud Schuit; Orestis A Panagiotou; Marcus R Munafò; Derrick A Bennett; Andrew W Bergen; Sean P David Journal: Cochrane Database Syst Rev Date: 2017-09-08